Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck & Co. Stock Surges on FDA Approval of WELIREG Plus LENVIMA

Guavy AI Editorial Team
Instruments
MRK
Share

Merck & Co.'s stock continued its upward trend on September 25, 2026, trading at USD 148.74 on the NYSE. This represents a daily change of 0.51 percent.

The company's pipeline received a boost with the U.S. FDA approval for WELIREG plus LENVIMA in certain previously treated patients with advanced renal cell carcinoma.

This regulatory milestone adds to Merck's oncology portfolio and follows the announcement on September 24, 2026, that remigromig met the primary endpoint in the BRUNELLO study for diabetic macular edema.

More on Stocks

Stocks just now

Thermal Interface Materials Market Sees Rapid Growth as Demand for Efficient Thermal Management Skyrockets

Stocks 1m ago

Honeywell Unveils P40 Upgrade for F-35 Fighter Jets with Enhanced Cooling Capacity

Stocks 1m ago

OT Cybersecurity Readiness Gap Exposed in Honeywell Report

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy